Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial)

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Abstract

An open controlled trial of the use of galantamine at a maximum dose of 16 mg/day included 41 patients with Parkinson's disease with dementia randomized to a galantamine treatment group (21 patients) and a control group (20 patients). Cognitive, neuropsychiatric, and motor symptoms were assessed clinically before the trial and at 4, 12, and 24 weeks, using the Mini Mental State Examination (MMSE), the cognitive Alzheimer's Disease Assessment Scale (ADAS-cog), the clock drawing test, the Frontal Assessment Battery (FAB), and the Neuropsychiatric Inventory (NPI) with assessment of distress in relatives. Patients treated with galantamine had better scores on the MMSE (p < 0.05),ADAS-cog (p < 0.05), the clock drawing test (p < 0.05), and the FAB (p < 0.01) at the end of the study period as compared with the control group. Changes in total point scores on the NPI-12 at the ends of weeks 12 and 24, as compared with the beginning of the trial, were in favor of the group treated with galantamine, with significant changes in the hallucinations (p = 0.0002), anxiety (p = 0.04), sleep disturbance (p = 0.04), and apathy (p = 0.006) sections. Galantamine treatment was accompanied by decreases in the level of distress in patients' relatives (p = 0.007) and improvements in daily activity (p = 0.003). Improvements in gait and decreases in freezing and falls were seen in the galantamine treatment group. However, two patients of this group showed minor increases in tremor. Side effects (drooling, postural hypotension, nausea, dysuria) occurred in seven patients (30%).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Zh. M. Glozman and O. S. Levin, “Mental disorders in extrapyramidal diseases,” in: Extrapyramidal Diseases: Handbook of Diagnosis and Treatment [in Russian], V. N. Shtok, I. A. Ivanova-Smolenskaya, and O. S. Levin (eds.), MEDpress-Inform, Moscow (2002), pp. 74–86.

    Google Scholar 

  2. V. L. Golubev, Ya. I. Levin, and A. M. Vein, Parkinson's disease and Parkinson's Syndrome [in Russian], MEDpress, Moscow (1999).

    Google Scholar 

  3. O. S. Levin and N. A. Amosova, Psychotic Disorders in Parkinson's disease. Scientific-Practical Conference on Parkinson's Disease [in Russian], Moscow (1999), pp. 30–32.

  4. O. S. Levin, “Efficacy of Reminyl in dementia with Lewy bodies,” Zh. Nevropatol. Psikhiat., 105, No. 10, 15–21 (2005).

    CAS  Google Scholar 

  5. D. Aarsland, J. P. Larsen, J. L. Cumming, et al., “Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease,” Arch. Neurol., 56, No. 3, 595–601 (1999).

    Article  PubMed  CAS  Google Scholar 

  6. D. Aarsland, K. Andersen, J. P. Larsen, et al., “Risk of dementia in Parkinson's Disease: A community-based prospective study,” Neurology, 56, No. 6, 730–736 (2001).

    PubMed  CAS  Google Scholar 

  7. D. Aarsland, M. Hutchinson, and J. P. Larsen, “Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia,” Int. J. Geriat. Psychiat., 18, No. 10, 937–941 (2003).

    Article  CAS  Google Scholar 

  8. C. Ballard, M. Piggott, and M. Johnson, “Delusions associated with elevated muscarinic binding in dementia with Lewy bodies,” Ann. Neurol., 48, No. 6, 868–876 (2000).

    Article  PubMed  CAS  Google Scholar 

  9. S. R. Beach and R. Schulz, “Caregiving as a risk factor for mortality: the Caregiver Health Effects Study,” J. Amer. Med. Assoc., 282, No. 23, 2215–2219 (1999).

    Article  Google Scholar 

  10. N. I. Bohnen, D. I. Kaufer, L. S. Ivanco, et al., “Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study,” Arch Neurol., 60: No. 12, 1745–1748 (2003).

    Article  PubMed  Google Scholar 

  11. N. I. Bohnen, D. I. Kaufer, R. Hendrickson, et al., “Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia,” J. Neurol., 253, No. 2, 242–247 (2005).

    Article  PubMed  CAS  Google Scholar 

  12. J. L. Boyd, C. A. Cruikshank, C. W. Kenn, et al., “Cognitive impairment and dementia in Parkinson's disease: a controlled study,” Psychol. Med., 21, No. 3, 911–921 (1991).

    PubMed  CAS  Google Scholar 

  13. R. Bullock and A. Cameron, “Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series,” Curr. Med. Res. Opin., 18, No. 5, 258–264 (2002).

    Article  PubMed  CAS  Google Scholar 

  14. M. J. Catalan-Alonso and J. Del Val, “Dopaminomimetic psychosis in Parkinson's disease: first symptom of early dementia?” Rev. Neurol., 32, No. 11, 1085–1087 (2001).

    PubMed  CAS  Google Scholar 

  15. J. L. Cummings, M. Mega, K. Gray, et al., “The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia,” Neurology, 44, No. 12, 2308–2314 (1994).

    PubMed  CAS  Google Scholar 

  16. C. Da Cunha, M. E. Angelucci, N. S. Canteras, et al., “The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities,” Cell Mol. Neurobiol., 22, No. 3, 227–237 (2002).

    Article  PubMed  Google Scholar 

  17. E. Duran Ferreras, J. Chacon, and J. A. Quintana, “The role of olanzapine in Parkinsonian dopaminergic psychosis,” Rev. Neurol., 35, No. 7, 691–696 (2002).

    PubMed  CAS  Google Scholar 

  18. K. R. Edwards, L. Hershey, and L. Wray, “Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis,” Dement. Geriat. Cogn. Disord., 17, Supplement 1, 40–48 (2004).

    Article  CAS  Google Scholar 

  19. R. L. Ernst and J. W. Hay, “The US economic and social costs of Alzheimer's disease revisited,” Amer. J. Public Health, 84, No. 8, 1261–1264 (1994).

    Article  PubMed  CAS  Google Scholar 

  20. G. Fabbrini, P. Barbanti, C. Aurilia, et al., “Donepezil in the treatment of hallucinations and delusions in Parkinson's disease,” Neurol. Sci., 23, No. 1, 41–43 (2002).

    Article  PubMed  CAS  Google Scholar 

  21. G. Fenelon, F. Mahieux, R. Huon, et al., “Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors,” Brain, 123, No. 7, 733–745 (2000).

    Article  PubMed  Google Scholar 

  22. J. M. Graham, R. A. Grunewald, and H. J. Sagar, “Hallucinosis,” J. Neurol. Neurosurg. Psychiat., 63, No. 5, 434–440 (1967).

    Google Scholar 

  23. D. Grossi, L. Trojano, and M. T. Pellecchia, “Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients,” Int. J. Geriat. Psychiat., 20, No. 7, 668–673 (2005).

    Article  Google Scholar 

  24. K. Ito, A. Nagano-Saito, T. Kato, et al., “Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study,” Brain, 125, No. 6, 1358–1365 (2002).

    Article  PubMed  Google Scholar 

  25. I. Leroi, J. Brandt, and S. G. Reich, “Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease,” Int. J. Geriat. Psychiat., 19, No. 1, 1–8 (2004).

    Article  Google Scholar 

  26. T. Mori, M. Ikeda, and R. Fukuhara, “Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB,” Neurology, 66, No. 6, 935–937 (2006).

    Article  PubMed  CAS  Google Scholar 

  27. K. Okada, N. Suyama, H. Oguro, et al., “Medication-induced hallucination and cerebral blood flow in Parkinson's disease,” J. Neurol., 246, No. 5, 365–368 (1999).

    Article  PubMed  CAS  Google Scholar 

  28. J. Parkinson, An Essay on the Shaking Palsy, Sherwood, Neely and Jones, London (1817), p. 66.

    Google Scholar 

  29. E. Perry, D. Irving, J. M. Kerwin, et al., “Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease,” Alzheimer. Dis. Assoc. Disord., 7, No. 2, 69–79 (1993).

    Article  PubMed  CAS  Google Scholar 

  30. I. H. Richard, A. W. Justus, N. H. Greig, et al., “Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine,” Clin. Neuropharmacol., 25, No. 6, 296–299 (2002).

    Article  PubMed  CAS  Google Scholar 

  31. M. Rosler, “The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia,” Int. J. Clin. Pract., 127, Supplement 1, 20–36 (2002).

    CAS  Google Scholar 

  32. A. J. Saykin, H. A. Wishart, and L. A. Rabin, “Cholinergic enhancement of frontal lobe activity in mild cognitive impairment,” Brain, 127, No. 7, 1574–1583 (2004).

    Article  PubMed  Google Scholar 

  33. W. S. Shaw, T. L. Patterson, and S. J. Semple, “Longitudinal analysis of multiple indicators of health decline among spousal caregivers,” Ann. Behav. Med., 19, No. 2, 101–109 (1997).

    Article  PubMed  CAS  Google Scholar 

  34. C. Summerfield, B. Gomez-Anson, E. Tolosa, et al., “Dementia in Parkinson's disease: a proton magnetic resonance spectroscopy study,” Arch., Neurol., 59, No. 9, 1415–1420 (2002).

    Article  Google Scholar 

  35. T. Sunderland, J. L. Hill, A. M. Mellow, et al., “Clock drawing in Alzheimer's disease: a novel measure of dementia severity,” J. Amer. Geriat. Soc., 37, No. 5, 725–729 (1989).

    PubMed  CAS  Google Scholar 

  36. P. N. Tariot, P. R. Solomon, J. C. Morris, et al., “A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group,” Neurol., 54, No. 12, 2269–2276 (2000).

    CAS  Google Scholar 

  37. E. Y. Uc, M. Rizzo, and S. W. Anderson, “Visual dysfunction in Parkinson disease without dementia,” Neurology, 65, No. 12, 1907–1913 (2005).

    Article  PubMed  CAS  Google Scholar 

  38. C. H. Van Dyck, P. Tariot, M. Farlow, et al., “Memantine/donepezil dual-therapy is superior to placebo/donepezil for treatment of moderate to severe Alzheimer's disease,” in: Abstracts of the 6th International Conference on Alzheimer's Disease and Parkinson's Disease, Seville, Spain (2003), p. 491.

  39. R. J. Van Marum and P. A. Jansen, “Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia,” Ned. Tijdschr. Geneeskd., 149, No. 4, 165–167 (2005).

    PubMed  Google Scholar 

  40. S. P. Woods and A. I. Troster, “Prodromal fontal/executive dysfunction predicts incident dementia in Parkinson's disease,” J. Int. Neuropsychol. Soc., 9, No. 1, 17–24 (2003).

    Article  PubMed  Google Scholar 

  41. C. Zarow, S. A. Lyness, J. A. Mortimer, and H. C. Chaul, “Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer's and Parkinson's diseases,” Arch. Neurol., 60, No. 3, 337–341 (2003).

    Article  PubMed  Google Scholar 

  42. I. Zhang, F. Zhou, and J. A. Dani, “Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release,” Mol. Pharmacol., 66, No. 3, 538–544 (2004).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nervous Diseases, Military Medical Academy, St. Petersburg, Russia

    I. V. Litvinenko, M. M. Odinak, V. I. Mogil’naya & A. Yu. Emelin

Authors
  1. I. V. Litvinenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. M. Odinak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. I. Mogil’naya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Yu. Emelin
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

__________

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 107, No. 12, pp. 25–33, December, 2007.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Litvinenko, I.V., Odinak, M.M., Mogil’naya, V.I. et al. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial). Neurosci Behav Physi 38, 937–945 (2008). https://doi.org/10.1007/s11055-008-9077-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-008-9077-3

Key Words

Search

Navigation